# Visum Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/visum-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Haikou, China
- Website: www.visumpharma.com
- Latest round: Series B (May 25, 2018)
- Investors on record: 2

## About

Based in Haikou, China and founded in 2010, Visum Pharmaceutical Co.,Ltd. operates as an innovative drug developer, integrating high-end oral solid dosage form development, production, export and sales. The company established 2 manufacturing centers, 2 research and development centers and 1 marketing center. There are 450 employees in the company. The company has passed GMP review by FDA 4 times and quality review by NMPA 3 times.

The company has created a technology R&D platform for slow and controlled release micro-pills, slow and controlled release skeleton tablets, and insoluble drugs. The company develops more than 80 types of products including slow and controlled release formulations, insoluble drugs and other drugs. Products within include metoprolol succinate extended-release tablets, quetiapine fumarate extended-release tablets, fenofibrate tablets, nateglinide tablets, repaglinide tablets fenofibrate tablets, nateglinide tablets, repaglinide tablets, aspirin dipyridamole capsules.

The company will focus on the continued research and development of high-end formulations and the construction of new cGMP workshops.

## Funding rounds

- Series B, May 25, 2018 — Hidea Investment, HighLight Capital

## Investors

- Hidea Investment (https://capitalatlas.ai/funds/hidea-investment) — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B